H. Léna

2001–2025 年に発表

別表記
H. Lena
51
論文数
21,256
被引用数
36
h 指数
49
i10 指数

被引用数

H. Léna の年別被引用数2000 年: 被引用 1 件2001 年: 被引用 1 件2002 年: 被引用 3 件2003 年: 被引用 7 件2004 年: 被引用 8 件2005 年: 被引用 18 件2006 年: 被引用 13 件2007 年: 被引用 22 件2008 年: 被引用 19 件2009 年: 被引用 13 件2010 年: 被引用 19 件2011 年: 被引用 21 件2012 年: 被引用 22 件2013 年: 被引用 38 件2014 年: 被引用 20 件2015 年: 被引用 80 件2016 年: 被引用 430 件2017 年: 被引用 486 件2018 年: 被引用 454 件2019 年: 被引用 1,201 件2020 年: 被引用 1,226 件2021 年: 被引用 1,104 件2022 年: 被引用 815 件2023 年: 被引用 563 件2024 年: 被引用 869 件2025 年: 被引用 418 件2026 年: 被引用 8 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,667 件、この内訳の 22%中国: 引用元論文 1,807 件、この内訳の 14.9%日本: 引用元論文 789 件、この内訳の 6.5%フランス: 引用元論文 744 件、この内訳の 6.1%イタリア: 引用元論文 717 件、この内訳の 5.9%イギリス: 引用元論文 548 件、この内訳の 4.5%ドイツ: 引用元論文 496 件、この内訳の 4.1%スペイン: 引用元論文 493 件、この内訳の 4%カナダ: 引用元論文 373 件、この内訳の 3.1%韓国: 引用元論文 353 件、この内訳の 2.9%オランダ: 引用元論文 330 件、この内訳の 2.7%スイス: 引用元論文 312 件、この内訳の 2.6%
0%22%その他 20.7%

分野

  • Medicine83.9%
  • Biochemistry, Genetics and Molecular Biology9.6%
  • Immunology and Microbiology4.7%
  • Engineering0.5%
  • Mathematics0.3%
  • Neuroscience0.2%
  • その他0.8%

トピック

  • Cancer Immunotherapy and Biomarkers19.2%
  • Lung Cancer Treatments and Mutations11.2%
  • Lung Cancer Research Studies9.4%
  • Lung Cancer Diagnosis and Treatment4.6%
  • Immunotherapy and Immune Responses4.4%
  • CAR-T cell therapy research2.8%
  • その他48.4%

共著者

全論文

検索で開く
  1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 9,459

  2. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sylvia Hartl, Maximilian J. Hochmair, Bernd Lamprecht, Michael Studnicka, Luís Alberto Schlittler, Fabrício Augusto Martinelli de Oliveira, Aknar Calabrich, Gustavo Girotto, Peo Dos Reis, Carlos Fausto Nino Gorini, Peo Rafael Martins De Marchi, Clarissa Baldotto, Cláudia Vaz de Melo Sette, Mauro Zukin, Nikolay Conev, Assen Dudov, Rumyana Ilieva, Krassimir Koynov, Rositsa Krasteva, Ivan Tonev, Spartak Valev, Violetka Venkova, Minghong Bi, Chengshui Chen, Yuan Chen, Zhendong Chen, Jian Fang, Jifeng Feng, Zhigang Han, Jie Hu, Yi Hu, Xing Li, Zongan Liang, Lin Zhong, Rui Ma, Shenglin Ma, Kejun Nan, Yongqian Shu, Kai Wang, Mengzhao Wang, Gang Wu, Nong Yang, Zhixiong Yang, Helong Zhang, Wei Zhang, Jun Zhao, Yanqiu Zhao, Caicun Zhou, Jianying Zhou, Xiangdong Zhou, Libor Havel, Vı́tězslav Kolek, Leona Koubková, Jaromı́r Roubec, Jana Skřičková, Milada Zemanová, C. Chouaïd, Werner Hilgers, H. Léna, Denis Moro‐Sibilot, G. Robinet, Pierre-Jean Souquet, Jürgen Alt, Helge Bischoff, Christian Grohé, Eckart Laack, Susanne Lang, Jens Panse, Niels Reinmuth, Christian Schulz ほか 146 名 - The Lancet 2019 被引用: 2,199

  3. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David Waterhouse, Luis Paz‐Ares - The Lancet 2023 被引用: 566

  4. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jean‐Charles Soria, Gérard Zalcman - The Lancet 2016 被引用: 984

  5. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2021 被引用: 156

  6. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 被引用: 1,429

  7. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Veerle Surmont, Martin Reck, Ji‐Youn Han, Esther Holgado Martin, Cristóbal Belda-Iniesta, Yuichiro Oe, Antonio Chella, Akhil Chopra, G. Robinet, Héctor Soto Parrà, Michael J. Thomas, Parneet Cheema, Nobuyuki Katakami, Wu‐Chou Su, Young‐Chul Kim, Juergen Wolf, Jong-Seok Lee, Hideo Saka, Michele Stanislaw Milella, Inmaculada Ramos García, Anne Sibille, Takashi Yokoi, Eun Joo Kang, Shinji Atagi, E. Spaeth-Schwalbe, Makoto Nishio, Fumio Imamura, Nashat Gabrail, Rémi Veillon, Sofie Derijcke, Tadashi Maeda, Dylan M. Zylla, Kendra Kubiak, Armando Santoro, Ma. Noemi Uy, Sarayut Lucien Geater, Antoîne Italiano, Dariusz M. Kowalski, Fabrice Barlési, Yuh‐Min Chen, David R. Spigel, Busyamas Chewaskulyong, Ramón García Gómez, Rosa Álvarez, Chih-Hsin Yang, Te‐Chun Hsia, Fabrice Denis, Hiroshi Sakai, Mark Vincent, Kōichi Goto, Joaquim Bosch‐Barrera, Glen J. Weiss, Jean-Luc Canon, Christian W. Scholz, Massimo Aglietta, Hirotsugu Kemmotsu, Koichi Azuma, Penelope A. Bradbury, Ronald Feld, Abraham Chachoua, Jacek Jassem, Rosalyn A. Juergens, Ramon Palmero Sanchez, Albert Malcolm, Nandagopal Vrindavanam, Kaoru Kubota, Cornelius F. Waller, David Waterhouse, Bruno Coudert, Z. Mark ほか 52 名 - The Lancet Oncology 2018 被引用: 576

  8. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel Brungs, Bo Gao, Adnan Nagria, Christos S. Karapetis, Sagun Parakh, Cheol Park, Gaëtan Catala, Frédéric Forget, Sebahat Ocak, Naveen S. Basappa, Geoffrey Liu, Ines B. Menjak, Benjamin Shieh, Shun Lü, Feng Luo, Hongmei Sun, Jialei Wang, Yu Yao, Milada Zemanová, Jaafar Bennouna, Nicolas Girard, Laurent Greillier, Corinne Lamour, H. Léna, Céline Mascaux, Julien Mazières, Denis Moro‐Sibilot, M. Pérol, Elvire Pons‐Tostivint, Virginie Westeel, Akin Atmaca, Christine Greil, Niels Reinmuth, Christian Schumann, Thomas Wehler, Juergen Wolf, James Ho, Csaba Böcskei, Federico Cappuzzo, Filippo de Marinis, Claudia Proto, Manlio Mencoboni, Silvia Novello, Stefania Salvagni, Héctor Soto Parrà, Haruko Daga, Yasushi Goto, Hidetoshi Hayashi, Satoru Kitazono, Kiyotaka Yoh, Ryo Ko, Masashi Kondo, Toshiyuki Kozuki, Takayasu Kurata, Hideaki Mizutani, Kadoaki Ohashi, Satoshi Oizumi, Isamu Okamoto, Satoshi Sakaguchi, H Ozasa, Shunichi Sugawara, Yuichi Tambo, Motohiro Tamiya, Hiroshi Tanaka, Isamu Okamoto, Froylán López-López, Francisco Javier Ramírez Godinez, Jerónimo Rafael Rodríguez Cid, Robin Cornelissen, Steven Gans ほか 61 名 - Journal of Clinical Oncology 2024 被引用: 182

  9. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anita Hiltbrunner, Mariana Pardo-Contreras, A. Gasca-Ruchti, Nino Giacomelli, Roswitha Kammler, Nesa Marti, Rita Pfister, Anne‐Christine Piguet, Susanne Roux, Sandra Troesch, M. Schneider, Robin Schweri, Isabel Zigomo, Zoi Tsourti, Panagiota Zygoura, S. Tsouprou, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Franck Morin, Elodie Amour, G. Mariaule, N. Archirel, María Dolores Arnaiz Fernández, E. Pereira, M. Fernandez, K. Lopez, Ainhoa Hernández, Sarah Chinchen, H. Jurkovic, Alan S. Livingstone, Jerry W. Mitchell, Macie B. Walker, Paul Mitchell, S. Ng, Christopher Steer, Karen Briscoe, Amina Saqib, Ehtesham Abdi, Baerin Houghton, Kenneth J. O’Byrne, B.R. Chittajallu, Brett Hughes, A. Black, Kristiaan Nackaerts, Henrica M.J. Werner, R. Gervais, Gérard Zalcman, F. Vaylet, P. Merle, I. Monnet, Denis Moro‐Sibilot, Olivier Molinier, Nicolas Girard, P.-J. Souquet, Fabrice Barlési, D. Debieuvre, Hélène Senellart, M. Poudenx, A. Dixmier, Damien Pouessel, Jacques Cadranel, H. Léna, Élisabeth Quoix, S. Friard, Clarisse Audigier-Valette, Julien Mazières, Éric Pichon, Martin Faehling ほか 20 名 - Annals of Oncology 2021 被引用: 114

  10. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 153

  11. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 被引用: 207

  12. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2016 被引用: 162

  13. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2011 被引用: 265

  14. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)

    著者: , , , , , , , , , - Annals of Oncology 2011 被引用: 245

  15. High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Benjamin Besse - Journal of Thoracic Oncology 2020 被引用: 55

  16. Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 被引用: 583

  17. Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 被引用: 350

  18. A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer

    著者: , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2008 被引用: 204

  19. Multicentre phase II study of cisplatin–etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study

    著者: , , , , , , , , , , - Annals of Oncology 2013 被引用: 176

  20. Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 407

  21. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2017 被引用: 135

  22. Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease

    著者: , , , , , , , , - Inflammation Research 2005 被引用: 247

  23. Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2018 被引用: 84

  24. LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2022 被引用: 39